By Damian Garde
February 5, 2015
Menlo Park, CA’s Armetheon raised a $24.3 million B round to support work on a new oral blood thinner the biotech believes can fill a hole in the blockbuster anticoagulant market.
The drug, tecarfarin, works by blocking an enzyme called VKOR that plays a role in blood clotting. In its Phase II trials, the tablet has so far avoided the side effects common in standard-of-care warfarin, Armetheon said. And the company believes it can make a meaningful difference for patients with prosthetic heart valves, a group often ineligible for next-generation drugs like Xarelto and Eliquis.